None listed
Conditions
Brief summary
Ultrasound assessment has improved the safety and accuracy of pleural procedures. Highly portable handheld ultrasound technology been developed, however has not been validated for this purpose. The aim of this study is to examine the ability of handheld ultrasound to determine a safe site for pleurocentesis. We hypothesize that the handheld ultrasound will be equivalent to the standard ultrasound.
Interventions
We will examine whether a highly portable handheld ultrasound would be able to determine a safe site with a standard point of care ultrasound used as the gold standard for diagnostic pleurocentesis. In this study, we will perform paired ultrasound assessments of patients with pleural effusions who are referred for diagnostic pleurocentesis. The intervention involves the patient undergoing two ultrasound assessments by a respiratory fellow and respiratory physician. The handheld ultrasound assessment is performed prior to the standard ultrasound assessment and takes approximately 5 to 10 minutes. This involves ultrasound gel on the side of the chest and the probe placed on the chest of the patient. A second assessor then performs the same ultrasound assessment with the standard ultrasound machine which also takes 5 to 10 minutes with the participant seated in the same location. Treatment will not be changed by the handheld ultrasound as the standard ultrasound will be used as the gold standard. The respiratory fellow and respiratory physician will be alternately allocated to either the handheld ultrasound or standard ultrasound machine.
Sponsors
Study design
Eligibility
Inclusion criteria
Stable consecutive patients, both inpatients and outpatients, with pleural effusions requiring diagnostic pleurocentesis alone or followed by therapeutic pleurocentesis, intercostal chest drain or indwelling tunnelled pleural catheter insertion will be prospectively recruited for this study
Exclusion criteria
Exclusion criteria include those patients on antiplatelet agents within the last seven days, anticoagulants or with an INR >1.5, pregnant patients, respiratory failure, platelet count of <100, patients unable to give informed consent